Thailand Updates Cosmetic Sample Import Rules and Recognized Facility-Inspection Bodies

Thailand's Cosmetics Control Group closed out January 2025 with two updates that don't touch a standard commercial cosmetic notification directly, but that matter a great deal to two specific groups of importers: brands bringing in cosmetic samples or exhibition units rather than product for sale, and manufacturers relying on a third-party facility inspection to satisfy Thai FDA's GMP expectations. Both changes are procedural rather than headline-grabbing, which is exactly why they get missed, and exactly why missing them creates real friction at the point a shipment or an audit actually happens.

The Sample and Exhibition Import Pathway, Revised

Thai FDA maintains a distinct, lighter-touch import pathway for cosmetic products that are not being brought into Thailand for commercial sale, most commonly product samples used for evaluation or formulation work, and display units intended for trade shows and exhibitions rather than retail shelves. Because these goods are not going to market, they don't require the full notification process a commercial shipment does, but they still require a defined procedure to clear customs and satisfy Thai FDA that the import is genuinely non-commercial.

On January 22, 2025, Thai FDA issued Edition 2 of the rules governing this pathway, amending the procedure that governs how a company documents and clears a sample or exhibition cosmetic shipment. Any brand that has used this pathway before, whether for R&D samples heading to a Thai formulation partner or display product for a Bangkok trade show, needs to confirm its documentation matches the revised Edition 2 procedure rather than assuming the version it used previously still applies unchanged. A pathway built specifically to move faster than a full notification loses that advantage quickly if the paperwork submitted doesn't match the current edition, and customs or Thai FDA staff processing the shipment have no reason to apply an outdated version on a company's behalf.

This matters more than it might first appear for brands still in the pre-market stage of entering Thailand. Sample imports are frequently how a company first tests a formulation with a local manufacturing or distribution partner, well before a commercial notification is ever filed, and exhibition units are how a brand tests market reception at a trade show before committing to a full launch. Getting the procedural details wrong at this early, lower-stakes stage creates delays that have nothing to do with the product itself and everything to do with a company working from the wrong edition of a rule that Thai FDA has already moved past.

The distinction between the two use cases is worth being precise about, because they are not interchangeable even though they share the same lighter-touch pathway. A sample import typically supports internal evaluation, formulation testing, or a manufacturing partner's own quality checks, none of which puts the product in front of a Thai consumer. An exhibition import supports a specific event, a trade show booth or a buyer meeting, where the product is on physical display but still not being sold. Thai FDA's revised procedure governs both, but a company should be clear internally about which category a given shipment falls under before it prepares the paperwork, since conflating the two, or misdescribing a shipment that is genuinely headed toward a commercial launch as a sample when it is really pre-positioning inventory, is the kind of mismatch that draws scrutiny rather than avoids it.

The Refreshed List of Recognized Facility-Inspection Bodies

Separately, on January 30, 2025, Thai FDA published an updated listing of the facility-inspection units it recognizes for cosmetics, the bodies a manufacturer can rely on to conduct a facility audit or GMP inspection whose results Thai FDA will actually accept as evidence of manufacturing-standard compliance. The same day, Thai FDA also issued a new order setting out the competency-evaluation rules that govern the assessors performing those inspections, establishing what standard an individual assessor has to meet before their inspection findings carry weight.

Together, these two January 30 releases define both halves of the same question: which organizations are currently authorized to conduct a recognized facility inspection, and what competency bar the people actually doing the inspecting have to clear. A manufacturer's GMP documentation is only as credible as the body that issued it, and Thai FDA periodically refreshes both of these lists as inspection bodies gain, lose, or renew their recognized status, or as assessor-competency standards themselves get revised. A facility audit conducted by a body that was recognized eighteen months ago but has since fallen off the current list does not carry the weight a manufacturer needs it to during a Thai FDA post-audit review, regardless of how rigorous the actual inspection was.

This is not an isolated event specific to cosmetics. Thai FDA refreshed several of its recognized third-party body lists across different regulated categories in early 2025, following a similar pattern to the accreditation refresh it ran for food and novel-food safety assessors around the same period. Read as a set, these refreshes point to Thai FDA actively tightening its oversight of the third-party bodies it delegates inspection and assessment work to, rather than treating recognized-body status as a fixed, one-time designation that never needs revisiting.

For a manufacturer, this pattern has a practical implication beyond the immediate January 2025 update: recognized-body status is not something to check once and file away. A facility inspection completed two or three years ago against a body that was properly recognized at the time does not automatically remain valid evidence indefinitely if that body's recognition has since lapsed or been revised. The safer operating assumption is that recognized-body and assessor-competency standards get revisited periodically, in cosmetics and in the other categories Thai FDA oversees, and that a manufacturer relying on an older inspection should re-confirm the inspecting body's current standing before submitting that inspection as supporting evidence in a new or renewed notification, not assume that what satisfied Thai FDA once will automatically satisfy it again.

Why This Matters Even When the Product Itself Hasn't Changed

Neither of these updates changes a single formulation requirement, ingredient restriction, or labeling rule for cosmetics sold in Thailand. That's precisely what makes them easy for a compliance team to overlook: nothing about the product itself is different, so nothing prompts a review of whether the surrounding procedural rules still match what the company is doing. But a sample shipment cleared under an outdated import procedure, or a GMP inspection conducted by a body that has since lost its recognized status, creates a documentation gap that surfaces at the worst possible moment, either at customs on a shipment a company assumed would clear routinely, or during a Thai FDA post-audit review of a notification the company assumed was fully supported.

The practical response is straightforward but requires active checking rather than passive assumption. Any brand with an upcoming sample or exhibition shipment should confirm its documentation reflects the January 22, 2025 Edition 2 procedure before the shipment moves, not after a customs hold raises the question. Any brand relying on a facility inspection to support its GMP position, whether for a first notification or an ongoing renewal, should confirm the inspecting body appears on Thai FDA's current recognized list and that the assessors involved meet the current competency-evaluation standard, rather than relying on the body's reputation or a prior engagement that predates these January 2025 updates.

What DeeMED Checks Before a Shipment or an Audit Proceeds

For clients moving cosmetic samples or exhibition product into Thailand, or relying on a facility inspection as part of their GMP file, DeeMED confirms the current procedural edition and the current recognized-body status directly against Thai FDA's own published lists before the shipment ships or the audit is scheduled, rather than after either one has already run into a problem. This is the same standing of a brand's Thai FDA local license holder, covered in our local license holder work, that determines who is on record with Thai FDA and accountable for exactly this kind of procedural detail. The rule that mattered eighteen months ago is not always the rule in force today, and Thai FDA's own publication history in early 2025 makes that point clearly.